| # | Drug | Count |
|---|---|---|
| 0 | CISPLATIN | 6 |
| 1 | NIVOLUMAB | 5 |
| 2 | CYCLOPHOSPHAMIDE | 2 |
| 3 | CYCLOPHOSPHAMIDE FOR INJECTION | 2 |
| 4 | CYCLOPHOSPHAMIDE INJECTION, SOLUTION | 2 |
| 5 | DOCETAXEL | 2 |
| 6 | DOCETAXEL ANHYDROUS | 2 |
| 7 | FLUOROURACIL | 2 |
| 8 | FLUOROURACIL CREAM, 0.5% | 2 |
| 9 | AMLODIPINE | 1 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | SELEGILINE HYDROCHLORIDE | 1 | 0.0017 |
| 1 | LEMBOREXANT | 1 | 0.0003 |
| 2 | VONOPRAZAN FUMARATE | 1 | 0.0001 |
| 3 | CISPLATIN | 6 | 0.0001 |
| 4 | NIVOLUMAB | 5 | 0.0001 |
| 5 | SODIUM BICARBONATE INJECTION, | 1 | 0.0000 |
| 6 | PIPERACILLIN SODIUM,TAZOBACTAM SODIUM | 1 | 0.0000 |
| 7 | DOCETAXEL ANHYDROUS | 2 | 0.0000 |
| 8 | DOCETAXEL | 2 | 0.0000 |
| 9 | FLUOROURACIL CREAM, 0.5% | 2 | 0.0000 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Orexin Receptor Antagonist [EPC] | 1 | 0.0001 |
| 1 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 5 | 0.0001 |
| 2 | Platinum-based Drug [EPC] | 7 | 0.0000 |
| 3 | CTLA-4-directed Blocking Antibody [EPC] | 1 | 0.0000 |
| 4 | Microtubule Inhibitor [EPC] | 3 | 0.0000 |
| 5 | Topoisomerase Inhibitor [EPC] | 1 | 0.0000 |
| 6 | Proteasome Inhibitor [EPC] | 1 | 0.0000 |
| 7 | Alkylating Drug [EPC] | 2 | 0.0000 |
| 8 | Calcineurin Inhibitor Immunosuppressant [EPC] | 1 | 0.0000 |
| 9 | Nucleoside Metabolic Inhibitor [EPC] | 2 | 0.0000 |